Indaptus Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
/ 
Frequently asked questions
To buy Indaptus Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Indaptus Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Indaptus Therapeutics Inc. is INDP:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Indaptus Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade Indaptus Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Indaptus Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Indaptus Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Indaptus Therapeutics Inc..